Seelos Therapeutics (SEEL)
(Delayed Data from NSDQ)
$1.07 USD
-0.06 (-4.89%)
Updated Jun 7, 2024 03:59 PM ET
After-Market: $1.11 +0.04 (3.74%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Seelos Therapeutics, Inc. [SEEL]
Reports for Purchase
Showing records 41 - 60 ( 65 total )
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Healthcare - Yas'' Weekly Recap of Our Key Notes
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Part 3: "Must-See" Companies at JPM (Mkt. Cap. <$100M) With 1Q20 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Expecting the Near-Term Focus to Be Advancing SLS-005 Into Phase 2b/3 Study in Sanfilippo
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
3Q19 PK PD Will Give the First Hints for What''s in Store for SLS-002
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
A New and Improved Game Plan for SLS-002 in Treating Suicidality
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
2Q19 Activities Show Progress Preparing for Initiation of a Potential SLS-005 Pivotal Study; Reiterate Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
2Q19 - Gaining Momentum with Key Program Updates
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Busy Beavers Continue to Build on Key Programs
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
1Q19 Recap: Third Quarter Is All About Execution
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y